Clinical Trial Update: LAMBDA 002 (Lung Registry) Study

View source ↗

Summary

The LAMBDA 002 (Lung Registry) study sponsored by Natera, Inc. is currently ACTIVE_NOT_RECRUITING, focusing on lung transplant rejection.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Transplant Rejection

Snippet

Sponsor: Natera, Inc. | Conditions: Lung Transplant Rejection | Status: ACTIVE_NOT_RECRUITING